12:00 AM
Oct 29, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Cinryze regulatory update

Health Canada approved an NDS from ViroPharma for Cinryze for routine prevention of angioedema attacks in adults and adolescents with hereditary angioedema (HAE)....

Read the full 95 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >